Intestinal failure-associated liver disease (IFALD) can lead to increased morbidity and mortality in patients with intestinal failure (IF). We report the case of a premature infant born at 25 weeks' gestation at a neighboring facility that developed surgical necrotizing enterocolitis and secondary IF with 6 cm of small bowel remaining measured from the ligament of treitz with jejunocolonic anastomosis. The patient's course was complicated by IFALD and transferred to our intestinal rehabilitation program at 3 months of age. He was treated with SMOF lipid in reduced lipid dosages to prevent and treat IFALD, including cycling of parenteral nutrition, monitoring of the glucose infusion rate, and adjusting the micronutrient, trace elements, and aggressive enteral feeding. Omegaven had not yet been approved during the time of this case presentation. During the course of his treatment, he experienced normalization of his liver profile tests and progressed toward enteral autonomy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jpen.2003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parenteral lipid emulsions: the state of the art.
Curr Opin Clin Nutr Metab Care
December 2024
Pain Management and Palliative Care, Department of Anesthesia, Intensive Care and Emergency, Molinette Hospital, University of Turin, Turin, Italy.
Purpose Of Review: Several types of injectable lipid emulsions (ILEs) have become available for parenteral nutrition. The purpose of this review is to highlight the most recent and interesting articles in the field of ILEs.
Recent Findings: Recent literature has compared ILEs in various clinical scenarios (e.
Prediction of chronic severe intestinal failure-associated liver disease by current criteria in adults: A descriptive cohort study.
JPEN J Parenter Enteral Nutr
December 2024
Intestinal Failure Unit, Salford Royal, NHS Foundation Trust, Salford, UK.
Introduction: Intestinal failure-associated liver disease covers a spectrum of conditions from mild to end-stage disease. Currently, there are 9 diagnostic criteria divided to four categories: cholestasis, steatosis, fibrosis, and unclassified. Our aim was to evaluate the application of these criteria to patients with chronic severe liver disease in patients with intestinal failure.
View Article and Find Full Text PDFIntestinal failure-associated liver disease model: a reduced phytosterol intravenous lipid emulsion prevents liver injury.
Pediatr Res
November 2024
Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA.
Background: Long-term parenteral nutrition in children often results in intestinal failure-associated liver disease (IFALD). Phytosterols are plant steroids in vegetable oil-based intravenous lipid emulsions (ILEs) that are associated with IFALD. We investigated whether a phytosterol-depleted soybean oil ILE, compared to standard soybean oil ILE, prevented hepatotoxicity in a murine IFALD model.
View Article and Find Full Text PDFFavorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats.
Pediatr Surg Int
November 2024
Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Article Synopsis
- This study looked at how clodronate, which affects vesicular nucleotide transport, impacts liver inflammation linked to intestinal failure in rats with short bowel syndrome.
- The researchers used a rat model that involved feeding them through a vein and surgically removing most of their small intestine, then giving them different doses of clodronate.
- Results showed that high doses of clodronate reduced liver fat and inflammation in the rats, suggesting potential benefits for patients with similar conditions related to intestinal failure.
Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models.
Pediatr Surg Int
October 2024
Department of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Purpose: This study aimed to investigate the effectiveness of dipeptidyl peptidase IV inhibitors (DPP4-I) against liver damage, especially fibrosis and lipid accumulation, in a rat intestinal failure-associated liver disease (IFALD) model.
Methods: SD rats were divided into two groups: the Control (n = 7; normal saline + IFALD model) and DPP4-I (n = 7; DPP4-I + IFALD model; short bowel syndrome (SBS) + total parenteral nutrition) groups. All rats were euthanized 21 days postoperatively to obtain tissue samples.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!